Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 8/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16224430 | 0.83 | MAP3K12 (0.58) | MAP3K12OPRL1 | |
| SCHEMBL31674941 | 0.83 | MAP3K12 (0.58) | MAP3K12OPRL1 | |
| SCHEMBL20147277 | 0.74 | MAP3K12 (0.78) | MAP3K12 | |
| SCHEMBL20147245 | 0.72 | MAP3K12 (0.80) | MAP3K12 | |
| SCHEMBL20147280 | 0.72 | MAP3K12 (0.80) | MAP3K12 | |
| SCHEMBL4420936 | 0.62 | CHRM3 (0.66) | MAP3K12 | |
| SCHEMBL4423538 | 0.62 | CHRM3 (0.66) | MAP3K12 | |
| SCHEMBL1286211 | 0.62 | PDE10A (0.50) | — | |
| SCHEMBL4425046 | 0.62 | CHRM3 (0.72) | MAP3K12 | |
| SCHEMBL25646824 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010549-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010549-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, HAX1 | MAP3K12 1980/4885OPRL1 872/4885DRD3 1056/4885 |
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | MAP3K12 1980/4885OPRL1 872/4885DRD3 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.